Fill Out Form to Receive Your Free Myeloma Awareness Ribbon

March is Myeloma Awareness Month

MAM 2014 web banner a1

Help spread awareness of myeloma by ordering a free March is Myeloma Awareness Month pin. Below are some facts you can share about myeloma during Myeloma Awareness Month:

  • Multiple myeloma (or myeloma) is the second most common blood cancer worldwide. It is called "multiple" because it is a cancer of the plasma cells and can occur at multiple sites.

  • Myeloma currently affects more than 100,000 people in the United States, with an estimated 20,000 new cases diagnosed each year.

  • Once a disease of the elderly, myeloma is now being found in increasing numbers in people under age 65.

Although we have seen important advances in the last decade, including the increased utilization of the sensitive and specific Freelite (sFLC) diagnostic test, there is still no cure for myeloma.

You can help increase awareness by displaying your March is Myeloma Awareness Month pin, which we will send to you free of charge, along with an information pamphlet created by the International Myeloma Foundation

 

myeloma awareness pinmarch is myeloma awareness month

 

ABOUT BINDING SITE

Binding Site is the manufacturer of the sole U.S. Food and Drug Administration-approved Freelite serum free light chain assay. Freelite is more sensitive than electrophoretic methods for detecting multiple myeloma and AL amyloidosis patients who often first present with renal failure. The NCCN Guidelines and the International Myeloma Working Group recommend the use of Freelite in the initial diagnostic workup of multiple myeloma and related disorders.1  

1. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.1.2014. © National Comprehensive Cancer Network, Inc. 2014. All rights reserved. Accessed February 13, 2014. To view the most recent and complete version of the guideline, go online to www.nccn.org.  NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.